Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free AKTX Stock Alerts

Akari Therapeutics (AKTX) Competitors

Akari Therapeutics logo
$16.65 -5.40 (-24.49%)
As of 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AKTX vs. NAII, APLT, LGVN, GNTA, and HOOK

Should you buy Akari Therapeutics stock or one of its competitors? MarketBeat compares Akari Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akari Therapeutics include Natural Alternatives International (NAII), Applied Therapeutics (APLT), Longeveron (LGVN), Genenta Science (GNTA), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry.

How does Akari Therapeutics compare to Natural Alternatives International?

Akari Therapeutics (NASDAQ:AKTX) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Akari Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -123.29% -63.01%
Natural Alternatives International -10.13%-12.21%-5.30%

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Natural Alternatives International has higher revenue and earnings than Akari Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Natural Alternatives International$129.86M0.13-$13.57M-$2.39N/A

Akari Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Akari Therapeutics presently has a consensus target price of $89.00, indicating a potential upside of 434.53%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Akari Therapeutics is more favorable than Natural Alternatives International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Akari Therapeutics had 12 more articles in the media than Natural Alternatives International. MarketBeat recorded 15 mentions for Akari Therapeutics and 3 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.97 beat Akari Therapeutics' score of -0.11 indicating that Natural Alternatives International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Natural Alternatives International
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Akari Therapeutics beats Natural Alternatives International on 7 of the 13 factors compared between the two stocks.

How does Akari Therapeutics compare to Applied Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, Akari Therapeutics had 15 more articles in the media than Applied Therapeutics. MarketBeat recorded 15 mentions for Akari Therapeutics and 0 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.11 indicating that Applied Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
Applied Therapeutics Neutral

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 30.7% of Akari Therapeutics shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Akari Therapeutics has higher earnings, but lower revenue than Applied Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A

Akari Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Akari Therapeutics currently has a consensus price target of $89.00, suggesting a potential upside of 434.53%. Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Akari Therapeutics' return on equity of -123.29% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -123.29% -63.01%
Applied Therapeutics N/A -340.84%-175.00%

Summary

Akari Therapeutics beats Applied Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Longeveron?

Akari Therapeutics (NASDAQ:AKTX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Akari Therapeutics presently has a consensus target price of $89.00, indicating a potential upside of 434.53%. Longeveron has a consensus target price of $5.50, indicating a potential upside of 611.51%. Given Longeveron's higher possible upside, analysts clearly believe Longeveron is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Longeveron
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Akari Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Akari Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Akari Therapeutics' return on equity of -123.29% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -123.29% -63.01%
Longeveron -1,844.49%-202.41%-140.67%

Akari Therapeutics has higher earnings, but lower revenue than Longeveron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Longeveron$1.20M14.99-$22.70M-$1.13N/A

In the previous week, Akari Therapeutics had 14 more articles in the media than Longeveron. MarketBeat recorded 15 mentions for Akari Therapeutics and 1 mentions for Longeveron. Longeveron's average media sentiment score of 1.89 beat Akari Therapeutics' score of -0.11 indicating that Longeveron is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
Longeveron Very Positive

Summary

Akari Therapeutics beats Longeveron on 7 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Genenta Science?

Akari Therapeutics (NASDAQ:AKTX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Akari Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, Akari Therapeutics had 13 more articles in the media than Genenta Science. MarketBeat recorded 15 mentions for Akari Therapeutics and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.43 beat Akari Therapeutics' score of -0.11 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
Genenta Science Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Akari Therapeutics presently has a consensus target price of $89.00, indicating a potential upside of 434.53%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Akari Therapeutics is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Genenta Science's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -123.29% -63.01%
Genenta Science N/A N/A N/A

Summary

Genenta Science beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to HOOKIPA Pharma?

HOOKIPA Pharma (NASDAQ:HOOK) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

HOOKIPA Pharma has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Akari Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HOOKIPA Pharma-785.66% -120.09% -77.14%
Akari Therapeutics N/A -123.29%-63.01%

63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by company insiders. Comparatively, 30.7% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akari Therapeutics has a consensus target price of $89.00, indicating a potential upside of 434.53%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than HOOKIPA Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HOOKIPA Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Akari Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HOOKIPA Pharma$9.35M1.49-$43.50M-$3.54N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

In the previous week, Akari Therapeutics had 15 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 15 mentions for Akari Therapeutics and 0 mentions for HOOKIPA Pharma. HOOKIPA Pharma's average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.11 indicating that HOOKIPA Pharma is being referred to more favorably in the media.

Company Overall Sentiment
HOOKIPA Pharma Neutral
Akari Therapeutics Neutral

Summary

Akari Therapeutics beats HOOKIPA Pharma on 8 of the 13 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

Export
MetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.19M$3.40B$6.42B$12.58B
Dividend YieldN/A2.28%2.75%5.26%
P/E RatioN/A18.9021.2926.31
Price / SalesN/A334.34562.18114.16
Price / CashN/A125.2643.4956.90
Price / Book1.337.2810.617.34
Net Income-$17.30M$24.20M$3.56B$336.95M
7 Day Performance-8.87%4.56%3.36%3.65%
1 Month Performance209.19%9.89%6.63%7.39%
1 Year Performance-67.86%64.06%36.99%37.74%

Akari Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKTX
Akari Therapeutics
2.014 of 5 stars		$16.65
-24.5%		$89.00
+434.5%		-57.6%$19.19MN/AN/A9
NAII
Natural Alternatives International
1.9404 of 5 stars		$2.56
-1.2%		N/A-20.2%$16M$129.86MN/A290
APLT
Applied Therapeutics
1.4191 of 5 stars		$0.10
flat		$1.00
+870.9%		N/A$15.86M$1MN/A30
LGVN
Longeveron
3.2633 of 5 stars		$0.67
-0.4%		$5.50
+716.9%		-36.1%$15.73M$1.20MN/A20
GNTA
Genenta Science
1.4595 of 5 stars		$0.62
-1.3%		N/A-79.3%$14.90MN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel